Diabetes

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, Hayashi, DPN, Diabetes, Patient, Dunker, Polyneuropathy, EKG

WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).

Key Points: 
  • WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN).
  • The reference standard for DPN was a gold standard nerve conduction study.
  • DPNCheck combined with CVR-R had high diagnostic performance with an area under the receiver operating curve of 0.88.
  • The authors concluded "The use of DPNCheck and electrocardiogram would make the diagnosis of DPN simple, ubiquitous, and with high reproducibility and reliability."

Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes

Retrieved on: 
Thursday, March 14, 2024
Diabetes, Health, Obesity, Disease, Patient, DSM-IV codes, CRS, Quality of life, Clinical trial, Safety, CSO, Ageing, Pharmaceutical industry

This clinical trial, conducted on both healthy volunteers and individuals with T2D, underscores the safety of ATR-258 as a novel β2-adrenoceptor agonist, offering a revolutionary approach to type 2 diabetes treatment.

Key Points: 
  • This clinical trial, conducted on both healthy volunteers and individuals with T2D, underscores the safety of ATR-258 as a novel β2-adrenoceptor agonist, offering a revolutionary approach to type 2 diabetes treatment.
  • The unique mechanism of action of ATR-258 enables the selective modulation of specific positive intracellular signaling pathways.
  • It underscores the therapeutic value of this novel pathway for the treatment of type 2 diabetes.
  • The final data demonstrated that ATR-258 was safe and well tolerated in healthy volunteers, and, importantly, also in the T2D patients.

CEO of Innovative Outcomes, Inc., (OTC:UBQU) Offers Open Letter to Shareholders and Investors

Retrieved on: 
Wednesday, March 13, 2024
Growth, Caregiver, Diabetes, Patient, Death, CBD, Insurance, Wound healing, OTC, CO, Hemp, Future, Amputation, Government, Health, Nursing

DENVER, CO, March 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Ubiquitech Software Corp. (OTC: UBQU) a dynamic and innovative software development company, is pleased to offer this open letter to shareholders and investors from the CEO of its new subsidiary Innovative Outcomes, Inc. (Innovative Outcomes) a prominent player in the multi-billion-dollar medical wound care industry.

Key Points: 
  • DENVER, CO, March 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Ubiquitech Software Corp. (OTC: UBQU) a dynamic and innovative software development company, is pleased to offer this open letter to shareholders and investors from the CEO of its new subsidiary Innovative Outcomes, Inc. (Innovative Outcomes) a prominent player in the multi-billion-dollar medical wound care industry.
  • CEO of Innovative Outcomes, Inc. Kevin Lamb: For the last 25 years my passion has focused on the medical industry; specifically, individuals who suffer from debilitating diabetes and vascular diseases.
  • This focus on “patients first” fulfills the mission of Innovative Outcomes, bridging the gap between medical professionals, insurance companies, and patients.
  • Follow Ubiquitech Software Corp, Inc. to learn more about Innovative Outcomes and stay informed about Company developments and growth:

ACADEMY OF NUTRITION AND DIETETICS CELEBRATES REGISTERED DIETITIAN NUTRITIONIST DAY MARCH 13 DURING NATIONAL NUTRITION MONTH

Retrieved on: 
Wednesday, March 13, 2024
Health, Dietitian, Conditional sentence, Education, Accreditation Council, Sport, Health equity, Diabetes, Patient, Research, Cancer, Food, Student, Kidney disease, Commission, CNAME record, Pediatrics, Table, Accreditation, Nursing

Chicago, March 13, 2024 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics celebrates the role of registered dietitian nutritionists as the food and nutrition experts during Registered Dietitian Nutritionist Day on March 13.

Key Points: 
  • Chicago, March 13, 2024 (GLOBE NEWSWIRE) -- The Academy of Nutrition and Dietetics celebrates the role of registered dietitian nutritionists as the food and nutrition experts during Registered Dietitian Nutritionist Day on March 13.
  • If my clients or patients can use these skills at home or away from home, I know I’ve accomplished my goal,” says registered dietitian nutritionist Kimberly Snodgrass, a national Academy Spokesperson in Detroit, Mich.
  • The Academy created Registered Dietitian Nutritionist Day to increase the awareness of RDNs as indispensable providers of food and nutrition services .
  • Representing more than 112,000 credentialed nutrition and dietetics practitioners, the Academy of Nutrition and Dietetics is the world’s largest organization of food and nutrition professionals.

Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care

Retrieved on: 
Tuesday, March 12, 2024
Diabetes, Chronic venous insufficiency, Patient, Mouth ulcer, Journal, JWC, Wound healing, Safety, CVI, Trial of the century

The study, a real-world, multicenter, retrospective clinical study, analyzed 18 hard-to-heal wounds in 11 patients who received Dermacyte Matrix between August 2022 and August 2023.

Key Points: 
  • The study, a real-world, multicenter, retrospective clinical study, analyzed 18 hard-to-heal wounds in 11 patients who received Dermacyte Matrix between August 2022 and August 2023.
  • All the patients in the study had failed to respond favorably to prior standard of care wound treatment.
  • The findings from this multicenter clinical study have been published in the March addition of the peer reviewed Journal of Wound Care (JWC).
  • Merakris also will present a poster at the JWC- sponsored CAMPs (Cellular Acellular and Matrix-Like Products) Wound Care Summit in Miami, Florida, March 13-14.

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

Retrieved on: 
Tuesday, March 12, 2024
Human, Conference, ATTD, CKD, Patient, Diabetes, EGFR, Safety, Chronic kidney disease, DKA, Hypoglycemia, Pharmaceutical industry

In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort.

Key Points: 
  • In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar to the total study cohort.
  • The efficacy and safety data were presented last week at ATTD 2024 - 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy.
  • Relative to placebo, treatment with sotagliflozin led to similar reductions in A1C, body weight and systolic blood pressure in the CKD and total cohorts.
  • “We are optimistic that sotagliflozin may become an important new treatment option for this important population.”

HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Retrieved on: 
Tuesday, March 12, 2024
Diabetes, ARIC, HSCS, Cardiovascular disease, Algorithm, Learning, Risk, Intelligence, Patient, Atherosclerosis, HF, Death, Type 2 diabetes, Type, Use, T2DM, Cardiovascular Diabetology, Medicine, Medical device

Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.

Key Points: 
  • Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.
  • Accordingly, the study sought to evaluate whether an AI-ECG model based on MyoVista® wavECG™ features was superior to NT-proBNP, as well as a conventional screening tool—the Atherosclerosis Risk in Communities (ARIC) HF risk score, in SBHF screening among patients with T2DM.
  • This independent study provides evidence of the clinical and diagnostic capabilities of AI-ECG, and specifically our MyoVista wavECG technology, to potentially advance current standards of care for heart screening in diabetic patients.” said Andrew Simpson, Chief Executive Officer of HeartSciences.
  • “Globally cardiovascular disease accounts for approximately one-third of all annual deaths and AI-ECG is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, not only for diabetic patients, but also for a significant number of at-risk patients.

GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY

Retrieved on: 
Tuesday, March 12, 2024
Transfer, Risk management, Certification, Biomedicine, Biomedical engineering, University, Diabetes, Senior management, Class, Commercial, Quality management system, Doctor of Philosophy, Process validation, Bachelor, Quality management, Sustainability, ISO, FDA

He will lead ISO-13485 certification and all related quality activities for the Company’s implantable Continuous Blood Glucose Monitoring (CBGM) technology.

Key Points: 
  • He will lead ISO-13485 certification and all related quality activities for the Company’s implantable Continuous Blood Glucose Monitoring (CBGM) technology.
  • “We are thrilled that Vincent has joined our growing team in this important leadership role.” said Paul Goode, PhD, CEO of Glucotrack.
  • Implementing a sustainable Quality Management System that will grow with us is essential as we now embark on product development activities for our commercial product.
  • I look forward to joining this leadership team to bring this differentiated technology to people with diabetes,” said Mr. Wong.

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Retrieved on: 
Tuesday, March 12, 2024
Human, Obesity, Disease, Diabetes, Weight loss, CTA, Mouse, T2D, Therapy, DSM-IV codes, Pharmaceutical industry

BURLINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform. RJVA-001 is the Company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.

Key Points: 
  • Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control.
  • These results with a native, short half-life human GLP-1 sequence to be used in RJVA-001 build upon earlier results with a prototype transgene GLP-1 analogue.
  • RJVA-001 is the Company’s first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D.
  • The Company has reached alignment with European regulators on the use of this efficacy model to support the submission of a Clinical Trial Application (CTA) in Europe.

ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY

Retrieved on: 
Tuesday, March 12, 2024
Absorption, Obesity, Diabetes, Human, Patient, Gastrointestinal tract, AREC, Semaglutide, Drug development, TRX, AIM, Peptide, Vaccine

Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.

Key Points: 
  • Oral delivery of this class of drug is extremely challenging owing to the proteolytic nature of the digestive system which significantly reduces bioavailability.
  • Using TRx Biosciences’ LipiCore™ oral delivery technology alongside Arecor’s formulation platform, Arestat™, the companies intend to jointly develop an oral GLP-1 receptor agonist product with enhanced physicochemical properties that can achieve higher oral bioavailability and stability.
  • Alongside TRx Biosciences and its expertise in targeted oral drug delivery, we have an opportunity to develop an enhanced oral GLP-1 receptor agonist product.
  • Success with semaglutide may offer a path to multiple oral peptide products with enhanced absorption and efficacy.”
    The collaboration provides scope for expansion, following the initial oral GLP-1 receptor agonist programme, to develop further oral peptide products.